Clinuvel Pharmaceuticals
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAClinuvel Pharmaceuticals (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders.
CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
Contact Details
Suite 3, Level 11, 535 Bourke Street, MELBOURNE VIC 3000
03 9660 4900
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 941st | Clinuvel Pharmaceuticals | -3% | -14% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Clinuvel Pharmaceuticals | $88.0m |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Guy Van Dievoet, Non-Executive Director | 30 Sep 2024 |
| NEW ROLE: Matthew Pringle, Non-Executive Director | 24 Sep 2024 |
| NEW ROLE: Pearl E Grimes, Non-Executive Director | 24 Sep 2024 |
| NEW ROLE: D. Keamy, | 04 Sep 2023 |
| NEW ROLE: Andrew Likierman, Non-Executive Director | 13 Apr 2022 |
| NEW ROLE: D.J. Wright, | 24 Nov 2020 |
| REMUNERATION UPDATE: Darren Keamy, Chief Finance Officer, Company Secretary | 13 Nov 2020 |
| NEW ROLE: Jeffrey Rosenfeld, Non-Executive Chairman, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Darren Keamy, Chief Finance Officer, Company Secretary | 03 Nov 2020 |
